EpiVax launches AI‑enhanced models to predict immunogenicity of biotherapeutics
Executive summary: EpiVax announced the launch of AI‑powered enhancements to its ISPRI™ in silico platform for predicting the immunogenic risk of biotherapeutic drugs. The update improves the speed and accuracy of immunogenicity screening, helping biopharma companies reduce late‑stage trial failures and accelerate drug development.
Who is involved: EpiVax Inc., its ISPRI™ platform team, and prospective biotech and pharmaceutical clients.
Likely next: The company expects early adoption by partner firms in Q4 2026 and plans further model refinements based on user feedback.
EpiVax has released AI‑enhanced updates to its ISPRI™ platform, expanding its capacity to forecast immunogenic responses for biotherapeutic candidates. The announcement was issued simultaneously in English, German and French, signaling a coordinated global rollout that follows an initial AI‑model launch in September. This cadence suggests an iterative development strategy rather than a single product drop. Immunogenicity remains a primary cause of clinical attrition and safety-related withdrawals for protein‑based drugs. By integrating machine‑learning algorithms trained on expanded epitope and HLA‑binding datasets, the updated models aim to improve the precision of T‑cell epitope identification and reduce false‑negative rates that can arise from conventional sequence‑only analyses. Regulatory agencies have increasingly signaled openness to qualified in silico tools for early risk assessment, which could accelerate the platform’s adoption in IND‑enabling packages. For EpiVax, the launch reinforces its competitive stance in the preclinical software market, where pharma and biotech partners seek scalable, reproducible immunogenicity screening. Near‑term developments to watch include publication of benchmarking studies against clinical outcomes, potential qualification submissions to FDA or EMA, and licensing agreements that would convert platform access into recurring revenue streams.
Timeline
- — EpiVax führt KI-gestützte Modelle zur Vorhersage der Immunogenität ein (PR Newswire)
- — EpiVax lance des modèles optimisés par l'IA pour la prédiction de l'immunogénicité (PR Newswire)
- — EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction (PR Newswire)
Key entities
Sources
Open the full interactive case file on Beyond →